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Introduction: The recommended target range for serum parathormone (PTH) in dialysis patients has changed from 150-300 pg/mL in the KDOQI guidelines to 2 to 9 times the upper limit of normal in the KDIGO ones. However, discussions about PTH reference values are needed. Indeed, reference values for serum PTH levels are generally obtained by measuring PTH in a population of apparently healthy subjects. Exclusion criteria for this population are highly important and should correspond to any potential cause of altered PTH secretion. In this study, we used the same reference population of vitamin D-replete normal subjects to establish reference values for 10 commercial PTH kits. We evaluated whether this may improve the classification of dialysis patients according to the KDIGO compared to the use of reference values proposed by the manufacturers.
Material and methods: We studied 149 haemodialysis patients undergoing dialysis 3 times a week. Blood was obtained just before a dialysis session and centrifuged within 30 minutes of blood sampling. Serum was aliquoted and stored at –80°C until assayed. One hundred-twenty women aged 48.6±15.2 years, and 120 men aged 51.5±17.5 years served as a reference population. All were Caucasians, apparently healthy, and were supplemented with vitamin D3 at various doses. Inclusion criteria were a 25OHD concentration (DiaSorin Liaison) ≥75 nmol/L, serum calcium and phosphate levels comprised between 2.15 and 2.60 and 0.74 and 1.51 mmol/L, respectively, and an estimated GFR (MDRD formula) ≥60 mL/min/1.73 m². The use of drugs known to influence bone and calcium/phosphorus metabolism was an exclusion criteria. We tested 10 different commercial PTH assays, of which two were 3rd-generation assays. Seven assays were fully automated and 3 were immunoradiometric assays. With each of these assays, PTH was measured according to the recommendations of the respective manufacturers. First, we classifyed the dialysis patients according to the KDOQI guidelines. Second, they were classified according to the new KDIGO guidelines, by multiplying by a factor 2 and 9 the upper reference range of each PTH assay as provided by the manufacturers. Third, we used the upper value of the reference range that we have established in our reference population for each PTH assay to classify the dialysis patients according to the KDIGO guidelines. Finally, we took the measurement uncertainty into consideration to classify the patients with our established reference range. 
Results: Our results show that, compared to the KDOQI, using the upper-normal limit provided by the manufacturers to determine the KDIGO range greatly improved the discrepancies in classifying the patients. Using the upper limit of our reference values to calculate the KDIGO target range moderately improved the classification of the patients. Taking the analytical variability into consideration, 8% of the patients only remained differently classified by the kits that yielded the most different absolute values. 
Conclusions: With 10 different methods for PTH determination, a global overall agreement in the classification of stage-5 CKD patients could be achieved with the KDIGO guidelines when the same vitamin-D replete population was used to establish the reference range.   





